NZ589733A - Oral administration of peripherally-acting opioid antagonists - Google Patents

Oral administration of peripherally-acting opioid antagonists

Info

Publication number
NZ589733A
NZ589733A NZ589733A NZ58973309A NZ589733A NZ 589733 A NZ589733 A NZ 589733A NZ 589733 A NZ589733 A NZ 589733A NZ 58973309 A NZ58973309 A NZ 58973309A NZ 589733 A NZ589733 A NZ 589733A
Authority
NZ
New Zealand
Prior art keywords
opioid
peripherally
oral administration
medicament
opioid antagonists
Prior art date
Application number
NZ589733A
Other languages
English (en)
Inventor
Kevin J Brodbeck
Alan R Kugler
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of NZ589733A publication Critical patent/NZ589733A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ589733A 2008-05-07 2009-05-07 Oral administration of peripherally-acting opioid antagonists NZ589733A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12686808P 2008-05-07 2008-05-07
PCT/US2009/002856 WO2009137086A1 (en) 2008-05-07 2009-05-07 Oral administration of peripherally-acting opioid antagonists

Publications (1)

Publication Number Publication Date
NZ589733A true NZ589733A (en) 2012-07-27

Family

ID=40888194

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ589733A NZ589733A (en) 2008-05-07 2009-05-07 Oral administration of peripherally-acting opioid antagonists

Country Status (15)

Country Link
US (1) US20110160239A1 (https=)
EP (1) EP2300009A1 (https=)
JP (1) JP2011519930A (https=)
KR (1) KR20110004425A (https=)
CN (1) CN102014907A (https=)
AU (1) AU2009244805B2 (https=)
BR (1) BRPI0912219A2 (https=)
CA (1) CA2723685C (https=)
EA (1) EA201001643A1 (https=)
IL (1) IL208794A0 (https=)
MX (1) MX2010011727A (https=)
MY (1) MY156913A (https=)
NZ (1) NZ589733A (https=)
WO (1) WO2009137086A1 (https=)
ZA (1) ZA201007531B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150037T4 (hr) 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
UA123856C2 (uk) * 2010-03-11 2021-06-16 Уайт Елелсі Фармацевтичні композиції метилналтрексону та натрію додецилсульфату для перорального введення
AU2011307608B8 (en) * 2010-09-30 2015-08-27 Grünenthal GmbH Crystalline naloxol-PEG conjugate
KR20140107540A (ko) * 2011-12-19 2014-09-04 샐릭스 파마슈티컬스 리미티드 메틸날트렉손의 경구 조성물을 사용하는 오피오이드 유발성 변비의 치료 및 예방 방법
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
CN104546791A (zh) * 2013-10-16 2015-04-29 辽宁亿灵科创生物医药科技有限公司 一种阿片受体拮抗剂的固体制剂及其制备方法
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
LT3137081T (lt) 2014-04-28 2018-02-26 Orphomed, Inc. Buprenorfino dimeras ir jo naudojimas gydant virškinamojo trakto sutrikimus
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2017092638A1 (zh) * 2015-12-01 2017-06-08 江苏恒瑞医药股份有限公司 阿片样受体拮抗剂类衍生物、其制备方法及其在医药上的应用
CN107033154B (zh) * 2016-02-02 2020-02-04 上海瀚迈生物医药科技有限公司 阿片受体拮抗剂缀合物及其应用
CN109134479A (zh) * 2017-06-27 2019-01-04 石家庄蒎格医药科技有限公司 结晶聚乙二醇纳洛酮草酸盐及制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
AU776567B2 (en) * 1999-11-01 2004-09-16 Evans, Brian K Composition for treatment of constipation and irritable bowel syndrome
ES2654819T3 (es) * 2001-10-18 2018-02-15 Nektar Therapeutics Conjugados poliméricos de antagonistas de opioides
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
EP2905033B1 (en) * 2003-12-16 2020-09-02 Nektar Therapeutics Monodisperse PEGylated naloxol compositions
KR101421747B1 (ko) * 2006-04-21 2014-07-30 넥타르 테라퓨틱스 모르피논의 입체선택적 환원
JP2010509227A (ja) * 2006-11-07 2010-03-25 ネクター セラピューティックス エイエル，コーポレイション オピオイド作動薬およびオピオイド拮抗薬の用量形態および同時投与

Also Published As

Publication number Publication date
CA2723685A1 (en) 2009-11-12
MY156913A (en) 2016-04-15
EP2300009A1 (en) 2011-03-30
BRPI0912219A2 (pt) 2015-10-06
MX2010011727A (es) 2010-11-30
EA201001643A1 (ru) 2011-06-30
AU2009244805A1 (en) 2009-11-12
ZA201007531B (en) 2012-03-28
AU2009244805B2 (en) 2013-01-10
IL208794A0 (en) 2010-12-30
WO2009137086A1 (en) 2009-11-12
US20110160239A1 (en) 2011-06-30
CA2723685C (en) 2016-09-27
CN102014907A (zh) 2011-04-13
KR20110004425A (ko) 2011-01-13
JP2011519930A (ja) 2011-07-14

Similar Documents

Publication Publication Date Title
NZ589733A (en) Oral administration of peripherally-acting opioid antagonists
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
NZ605888A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
MX2009009131A (es) Mejoras en y con relacion a composiciones medicinales.
PH12013501341A1 (en) Morphinan compounds
UA93543C2 (ru) Применение дозированной лекарственной формы, которая содержит оксикодон и налоксон
MX2009009133A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y naloxona.
MY149731A (en) Compounds
MX2011013902A (es) Tratamiento de esclerosis multiple con laquinimod.
NZ595467A (en) Sublingual pharmaceutical composition comprising a neutral oil
WO2012079092A3 (en) Testosterone undecanoate compositions
PH12013501244A1 (en) A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
MX2009009132A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona.
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
MX350304B (es) Metodos para reducir la ingesta excesiva o comer compulsivamente.
UA109781C2 (uk) Сигма-ліганди для потенціювання аналгетичного ефекту опіоїдів і опіатів при післяопераційному болю і для послаблення залежності від них
NZ719087A (en) Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
MY150599A (en) [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase
MY154591A (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
NZ596161A (en) Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
MX347237B (es) Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina.
MX2009009134A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y nalmefeno.
MY148084A (en) Substituted carboxamides as group i metabotropic receptor antagonists
WO2009019693A3 (en) Analgesic effect of jasmonate derivatives
NZ598783A (en) Use of opioid receptor antagonist for gastrointestinal tract disorders

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 07 MAY 2016 BY CPA GLOBAL

Effective date: 20130322

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2017 BY CPA GLOBAL

Effective date: 20160330

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2018 BY THOMSON REUTERS

Effective date: 20170421

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2019 BY THOMSON REUTERS

Effective date: 20180418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2020 BY THOMSON REUTERS

Effective date: 20190417

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2021 BY THOMSON REUTERS

Effective date: 20200417

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2022 BY THOMSON REUTERS

Effective date: 20210403

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2023 BY THOMSON REUTERS

Effective date: 20220402

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2024 BY THOMSON REUTERS

Effective date: 20230403

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2025 BY THOMSON REUTERS

Effective date: 20240401

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2026 BY THOMSON REUTERS

Effective date: 20250402